Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

China · Delayed Price · Currency is CNY

23.79

+0.68 (2.94%)

Nov 5, 2026, 4:00 PM EST

Market Cap	2.11B -34.3%
Revenue (ttm)	375.19M -14.6%
Net Income	-47.19M
EPS	-0.53
Shares Out	88.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.22 (0.92%)
Ex-Dividend Date	May 29, 2026

Volume	1,284,201
Open	22.71
Previous Close	23.11
Day's Range	22.71 - 23.98
52-Week Range	21.70 - 38.31
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About SHE:301258

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; L-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonst... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 540

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301258

Full Company Profile

Financial Performance

In 2025, SHE:301258's revenue was 432.73 million, an increase of 0.76% compared to the previous year's 429.47 million. Earnings were 64.29 million, an increase of 291.89%.

Financial Statements